Showing 4391-4400 of 5771 results for "".
- NextGen Launches a Dedicated Optometric Workflow in its Fully Integrated Eye Care Platformhttps://modernod.com/news/nextgen-launches-a-dedicated-optometric-workflow-in-its-fully-integrated-eye-care-platform/2478643/NextGen Healthcare announced it has launched a dedicated optometric workflow in its fully integrated eye care platform. This new optometric software solution is part of the NextGen Ophthalmic Suite, which integrates b
- Canada Authorises Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/canada-authorises-pfizer-biontechs-covid-19-vaccine/2478645/Health Canada announced that it has authorized Pfizer and BioNTech’s mRNA-based coronavirus vaccine BNT162b2 (tozinameran) under an interim order for emergency use, becoming the third country to do so after the UK and Bahrain. The initial indication of the vaccine in Canada is for use in pe
- The Cassini Ambient Now Compatible With the Catalys Precision Laser Systemhttps://modernod.com/news/the-cassini-ambient-now-compatible-with-the-catalys-precision-laser-system/2478642/Cassini Technologies announced that the compatibility between the latest cOS 6.0 software for the Catalys Precision Laser System and the Cassini Ambient is ready for market launch. The Cassini Ambient and Catalys Precision Laser System will be jointly promoted as part of a collaboration agreement
- “A Lifestyle Epidemic: Ocular Surface Disease” Workshop To Address Vision-Compromising Challengeshttps://modernod.com/news/a-lifestyle-epidemic-ocular-surface-disease-workshop-to-address-vision-compromising-challenges/2478639/The Tear Film & Ocular Surface Society (TFOS) announced their next global workshop, entitled “A Lifestyle Epidemic: Ocular Surface Disease.” The World Health Organization indicates that eye problems are increasingly linked to lifestyle choices.1 Lifestyle diseases are
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- SIFI Appoints Jelle Kleijn to Lead Effort to Deliver First Registered Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-appoints-jelle-kleijn-to-lead-effort-to-deliver-first-registered-treatment-of-acanthamoeba-keratitis/2478631/SIFI has announced the recent appointment of Jelle Kleijn, PhD, as Global Head of Acanthamoeba keratitis. Dr. Kleijn will lead the efforts aimed at developing and making polihexanide monotherapy available to Acanthamoeba keratitis (AK) patients. Given the urgency to effectively treat AK to
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and
- CMS Confirms Continued Separate Payment for Omeros’ Omidria in Ambulatory Surgery Centershttps://modernod.com/news/cms-confirms-continued-separate-payment-for-omeros-fda-approved-omidria-in-ambulatory-surgery-centers/2478625/Omeros announced that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. In its final rule directed to the Medicare outpatient
- InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoidshttps://modernod.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/InMed Pharmaceuticals announced that it has secured an exclusive, worldwide license from EyeCRO for its Microemulsion Drug Ocular Penetration System (MiDROPS) eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. EyeCRO is a contract research o
- FDA Approves Eyenovia’s IND Application for MicroLine for Presbyopia, Allowing for Phase 3 Trialshttps://modernod.com/news/fda-approves-eyenovias-ind-application-for-microline-for-presbyopia-allowing-for-phase-3-trials/2478620/Eyenovia announced that the FDA has accepted its investigational new drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in near vision in patients with presbyopia. The company intends to initiate the phase 3 VISION program, beginning with the VISION-1